Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-10887.38%
operating margin TTM
-7796.57%
revenue TTM
1.27 Million
revenue per share TTM
0.05$
valuation ratios | |
|---|---|
| pe ratio | -0.22 |
| peg ratio | -0.00 |
| price to book ratio | -0.16 |
| price to sales ratio | 53.56 |
| enterprise value multiple | 0.86 |
| price fair value | -0.16 |
profitability ratios | |
|---|---|
| gross profit margin | 51.25% |
| operating profit margin | -7796.57% |
| pretax profit margin | -10887.38% |
| net profit margin | -10887.38% |
| return on assets | -155.62% |
| return on equity | 73.15% |
| return on capital employed | 555.54% |
liquidity ratios | |
|---|---|
| current ratio | 0.83 |
| quick ratio | 0.82 |
| cash ratio | 0.53 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 841.95 |
| operating cycle | 974.42 |
| days of payables outstanding | 17,143.34 |
| cash conversion cycle | -16,168.92 |
| receivables turnover | 2.76 |
| payables turnover | 0.02 |
| inventory turnover | 0.43 |
debt and solvency ratios | |
|---|---|
| debt ratio | 2.44 |
| debt equity ratio | -1.15 |
| long term debt to capitalization | -7.84 |
| total debt to capitalization | 7.76 |
| interest coverage | -3.85 |
| cash flow to debt ratio | -0.53 |
cash flow ratios | |
|---|---|
| free cash flow per share | -4.72 |
| cash per share | 2.33 |
| operating cash flow per share | -4.72 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.53 |
| short term coverage ratios | -2.31 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time BioXcel Therapeutics, Inc. (NASDAQ:BTAI) reported earnings?
BioXcel Therapeutics, Inc. (BTAI) published its most recent earnings results on 12-11-2025.
What is BioXcel Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. BioXcel Therapeutics, Inc. (NASDAQ:BTAI)'s trailing twelve months ROE is 73.15%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. BioXcel Therapeutics, Inc. (BTAI) currently has a ROA of -155.62%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did BTAI's net profit margin stand at?
BTAI reported a profit margin of -10887.38% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is BTAI's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 0.83 in the most recent quarter. The quick ratio stood at 0.82, with a Debt/Eq ratio of -1.15.